Loading
JPXConsumer DefensiveBeverages - Non-Alcoholic
Latest quote
¥2,816
−¥13.00 · -0.46%
Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the manufacturing and sale of a broad array of products, including food and beverages, cosmetics, and pharmaceuticals. The company's operations are segmented geographically for its Food and Beverages division, covering Japan, the Americas, Asia and Oceania, and Europe, alongside dedicated Pharmaceutical and "Others" segments. Its extensive food and beverage offerings feature popular items such as fermented milk beverages, various juices, and noodle products, which are distributed through both a home delivery service and traditional retail channels. In the pharmaceutical sector, Yakult Honsha provides specific medications like the antineoplastic drug Elplat, along with a suite of generic anti-cancer treatments, including Gemcitabine Yakult, Capecitabine, and Gefitinib Yakult tablets. Furthermore, the company maintains a presence in the cosmetics industry and is notably the owner of the professional baseball team, the Tokyo Yakult Swallows. Founded in 1935, Yakult Honsha Co.,Ltd. is headquartered in Tokyo, Japan.
Latest quote
¥2,816
−¥13.00 · -0.46%
Regular session · JST · Market data may be delayed.
Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the manufacturing and sale of a broad array of products, including food and beverages, cosmetics, and pharmaceuticals. The company's operations are segmented geographically for its Food and Beverages division, covering Japan, the Americas, Asia and Oceania, and Europe, alongside dedicated Pharmaceutical and "Others" segments. Its extensive food and beverage offerings feature popular items such as fermented milk beverages, various juices, and noodle products, which are distributed through both a home delivery service and traditional retail channels. In the pharmaceutical sector, Yakult Honsha provides specific medications like the antineoplastic drug Elplat, along with a suite of generic anti-cancer treatments, including Gemcitabine Yakult, Capecitabine, and Gefitinib Yakult tablets. Furthermore, the company maintains a presence in the cosmetics industry and is notably the owner of the professional baseball team, the Tokyo Yakult Swallows. Founded in 1935, Yakult Honsha Co.,Ltd. is headquartered in Tokyo, Japan.
Day range
Current ¥2,816
52-week range
Current ¥2,816
Regular session · JST · Market data may be delayed.
Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the manufacturing and sale of a broad array of products, including food and beverages, cosmetics, and pharmaceuticals. The company's operations are segmented geographically for its Food and Beverages division, covering Japan, the Americas, Asia and Oceania, and Europe, alongside dedicated Pharmaceutical and "Others" segments. Its extensive food and beverage offerings feature popular items such as fermented milk beverages, various juices, and noodle products, which are distributed through both a home delivery service and traditional retail channels. In the pharmaceutical sector, Yakult Honsha provides specific medications like the antineoplastic drug Elplat, along with a suite of generic anti-cancer treatments, including Gemcitabine Yakult, Capecitabine, and Gefitinib Yakult tablets. Furthermore, the company maintains a presence in the cosmetics industry and is notably the owner of the professional baseball team, the Tokyo Yakult Swallows. Founded in 1935, Yakult Honsha Co.,Ltd. is headquartered in Tokyo, Japan.
Day range
Current ¥2,816
52-week range
Current ¥2,816
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 486.43B JPY | 499.68B JPY | 503.08B JPY | 483.07B JPY | 415.12B JPY |
| Cost of goods sold | 200.19B JPY | 204.16B JPY | 203.17B JPY | 194.59B JPY | 166.7B JPY |
| Gross profit | 286.24B JPY | 295.52B JPY | 299.91B JPY | 288.48B JPY | 248.42B JPY |
| Research and development | — | 9.4B JPY | 9.1B JPY | 9.38B JPY | 8.66B JPY |
| Selling, general, and administrative | 241.05B JPY | 225.84B JPY | 222.79B JPY | 208.48B JPY | 182.03B JPY |
| Operating expenses | 241.29B JPY | 240.13B JPY | 236.51B JPY | 222.41B JPY | 195.22B JPY |
| Interest income | 9.25B JPY | 13.08B JPY | 11.59B JPY | 6.04B JPY | 3.31B JPY |
| Interest expense | 1.3B JPY | 874M JPY | 660M JPY | 666M JPY | 680M JPY |
| Depreciation and amortization | 28.81B JPY | 29.98B JPY | 27.84B JPY | 25.33B JPY | 23.77B JPY |
| Operating income | 44.95B JPY | 55.39B JPY | 63.4B JPY | 66.07B JPY | 53.2B JPY |
| Net income | 44.23B JPY | 45.53B JPY | 51.01B JPY | 50.64B JPY | 44.92B JPY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
¥65.00
2025 complete year+109.7% since 2021
2026 partial: ¥37.00
¥31.00
2,021
¥40.50
2,022
¥50.00
2,023
¥60.00
2,024
¥65.00
2,025
¥37.00
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Sep 29, 2026 | ¥36.00Annual | Sep 30, 2026 | Sep 29, 2026 |
DividendUpcoming | Mar 30, 2027 | ¥36.00Semi-Annual | Mar 31, 2027 | Mar 30, 2027 |
Dividend | Mar 30, 2026 | ¥37.00Special | Mar 31, 2026 | Jun 5, 2026 |
Dividend | Sep 29, 2025 | ¥33.00Semi-Annual | Sep 30, 2025 | Dec 5, 2025 |
Dividend | Mar 28, 2025 | ¥32.00Semi-Annual | Mar 31, 2025 | Jun 6, 2025 |
Dividend | Sep 27, 2024 | ¥32.00Semi-Annual | Sep 30, 2024 | Nov 29, 2024 |
Ex-dividend Sep 29, 2026
¥36.00
Annual
Record Sep 30, 2026 · Payment Sep 29, 2026
Ex-dividend Mar 30, 2027
¥36.00
Semi-Annual
Record Mar 31, 2027 · Payment Mar 30, 2027
Ex-dividend Mar 30, 2026
¥37.00
Special
Record Mar 31, 2026 · Payment Jun 5, 2026
Ex-dividend Sep 29, 2025
¥33.00
Semi-Annual
Record Sep 30, 2025 · Payment Dec 5, 2025
Ex-dividend Mar 28, 2025
¥32.00
Semi-Annual
Record Mar 31, 2025 · Payment Jun 6, 2025
Ex-dividend Sep 27, 2024
¥32.00
Semi-Annual
Record Sep 30, 2024 · Payment Nov 29, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T1.82B0.06%2.91T JPY0.05%¥413.5-0.48%
iShares JPX-Nikkei 400 ETF1364.T555.33M0.09%595.24B JPY0.05%¥3,707-0.19%
Vanguard Total International Stock ETFVXUS61.87M0.01%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Developed Markets ETFVEA41.25M0.01%315B USD0.03%$72.69+1.07%
iShares Core MSCI EAFE ETFIEFA33.52M0.02%193.07B USD0.07%$99.50+1.00%
iShares MSCI EAFE Small-Cap ETFSCZ14.66M0.11%12.89B USD0.40%$86.09+0.87%
State Street SPDR Portfolio Developed World ex-US ETFSPDW12.58M0.03%42.01B USD0.03%$51.56+1.12%
Schwab International Equity ETFSCHF10.18M0.01%69.45B USD0.03%$28.19+1.11%iShares Core TOPIX ETF1475.TiShares JPX-Nikkei 400 ETF1364.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZState Street SPDR Portfolio Developed World ex-US ETFSPDWSchwab International Equity ETFSCHFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
